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Abstract 
Objective: 6-Mercaptopurine (6-MP) is a cancer chemotherapeutic agent. Metabolic pathway by 
thiopurine S-methyltransferase (TPMT) to become 6-methylmercaptopurine (6-MMP).Bio-sampling is 
required to obtainbiological sample, using two technique; invasive (venipuncture) and minimum 
invasive(dried blood spot). This study aims to obtain an optimization and validation analysis 6-MP and 
6-MMP in vitro study with bio-sampling venipuncture and dried blood spot (DBS). Method: Plasma from 
venipuncture method extraction was done using dichloromethane. Separation was performed using 
Waters HPLC, C18 SunfireTM column (5μm, 250 x 4.6 mm), with gradient elution, flow rate 1 mL/min 
and detected at UV-PDA wavelength of 303 nm. Bio-sampling dried blood spot with DBS CAMAG® 
paper diameter of 8 mm and extracted with acetonitrile-methanol (1:3). Separation was performed with 
Waters LC-MS/MS UPLC C18 column (1.7 μm, 2.1 x 100 mm) with gradient elution, flow rate 0.2 
mL/min. 5-fluorouracil (5-FU) was used as internal standard.Result: The method venipuncture was 
linear at concentration range of 2-200 ng/mL for 6-MP and 20-2000 ng/mL for 6-MMP. The method dried 
blood spot using Waters Xevo TQD for mass detection with positive electrospray ionization (ESI) for 6-
MP, 6-MMP and negative ESI for 5-FU in Multiple Reaction Monitoring mode. Linear with the range 26-
1000 ng/mL for 6-MP and 13-500 ng/mL for 6-MMP.Conclusion: The developed method is valid for 6-MP 
and 6-MMP simultaneously in vitro from venipuncture using HPLC and from dried blood spot using LC-
MS/MS and showed good selectivity, linearity, accuracy and precision, matrix effect and stability. 
Keywords: 6-mercaptopurine, 6-methylmercaptopurine, Venipuncture, Dried blood spot.  
 
Introduction 
One of method that can be used to 
therapeutic drug monitoring is bioanalysis. 
Bioanalysis is a drug and metabolite analysis 
method in biological sample, such as; blood, 
plasma, and saliva [1]. 
 
Biological sample can be obtained with bio-
sampling venipuncture method, taking blood 
from vein with syringe [2]. The other bio-
sampling method is dried blood spot, 
collecting blood with minimum invasive 
through fingers, toes or heal, then  blood 
samples blotted and dried on special paper, 
then can be stored or directly analyzed.[3]6-
Mercaptopurine (6-MP) is a cancer 
chemotherapeutic agent. Metabolic pathway 
by thiopurine S-methyltransferase (TPMT) to 
become 6-methylmercaptopurine (6-MMP), 6-
MP also displays a range of possible adverse 
drug reactions and a narrow therapeutic 
index. Hence, the therapeutic index for each 
individuals need to be monitored [4]. 6-
Mercaptopurin is cytostatic drug that has 
narrow therapeutic index, so it requires 
therapeutic drug monitoring.  
 
Therefore, therapeutic drug monitoring of 6-
MMP is required to estimate that 6-MMP 
concentration is at a safe range. Common 6-
mercaptopurine dose given to a child suffers 
from ALL is 50-75 mg/m2, variety of doses 
implies to patients depend on body surface 
area[5].This study aims to obtain an 
optimization and validation analysis in vitro 
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study 6-MP and 6-MMP with bio-sampling 
venipuncture and dried blood spot. Analysis 
of 6-mercaptopurine and its metabolites in 
erythrocytes and plasma with venipuncture 
using HPLC has been developed, these 
methods have difficult and complex 
extraction with derivatization 
procedure[2,6].This research developed a 
simple extraction, quick, and accurate 
analytical methods of 6-mercaptopurine and 
6-methylmercaptopurine with 5-fluorouracil 
as internal standard simultaneously using 
HPLC. The sample preparation used liquid-
liquid extraction.  
 
There is no report described the development 
of an analytical method to determine 6-MP in 
DBS. This method has the advantage of 
minimum pain for patients, for the blood is 
taken using sterile needle lancet on the 
fingers, toes, and heels. Another advantage is 
the small amount of blood taken (10-80 µL), 
dried blood sample also has convenience in 
storage and distribution, analyses in a 
sample of dried blood is relatively stable, As 
well as reduce the risk of infection and 
convenient to the subject [7].Analytical 
method of 6-MP and 6-MMP simultaneously 
in dried blood spot sample with UPLC-
MS/MS using 5-fluorouracil as internal 
standard. The sample preparation was using 
protein precipitation. 
Materials and Methods 
Chemicals and Reagent 
6-Mercaptopurine (6-MP), 6-
methylmercaptopurine (6-MMP), 5-fluo-
rouracil (5-FU) were obtained from Sigma 
Aldrich (St. Louis, MO, USA), acetonitrile 
HPLC grade,methanol HPLC grade, formic 
acid, ammonium acetate, NH4OH, 
dichloromethane were purchased from 
Merck(USA),purified water was prepared by 
a Millipore Direct-QTM 5 water system 
(Millipore, Watford, UK), sampling paper 
DBS was purchased from CAMAG, plasma 
and whole blood from a blood bank 
(Indonesian Red Cross, Indonesia). 
Instruments and Chromatographic 
Conditions 
High performance liquid chromatography 
(HPLC) consists of separation module 
(Alliance 2996; Waters), column heater 
(Alliance series; Waters), and photodiode 
array detector (Waters 2996). The data were 
acquired and analyzed using Empower TM 
software. Separation of 6-MP and 6-MMP 
was achieved using reverse phase analytical 
column (C-18 Sun fire™, 5 μm; 250 x 4.6 
mm). There are two mobile phase mobile 
phase A consists of water-methanol (90:10) 
and mobile phase B consists of water-
acetonitrile (75:25). Samples separation was 
performed with gradient elution. The 
samples were eluted with mobile phase A at 
the first 6 min and changed to mobile phase 
B in 7-13.5 min. Elution was continued with 
mobile phase A to the end of the run at 16 
min. Flow rate were maintained at 1 mL/min 
with column temperature of 30°C.  
 
The photodiode array detector was set at 
wavelength of 303 nm. Liquid 
chromatography-tandem mass spectrometry 
(LC-MS/MS) was performed on Waters 
Acquity® UPLC BEH (Bridged Ethylene 
Hybrid) C18 column 1, 7 μm (2,1 mm x 100 
mm). The flow rate was 0.2 mL/min using a 
gradient elution starting with 95% water 
with 0.1% formic acid and 5% acetonitrile 
with 0.1% formic acid. The mass selective 
detector operated in electrospray ionization 
(ESI) positive mode for 6-MP and 6-MMP, a 
negative mode for internal standard (5-FU). 
Mass spectrometric detection was performed 
on Waters Xevo TQD Triple Quadrupole 
(Waters, Milford, USA), multiple reaction 
monitoring (MRM) was employed with mass 
resolutions of wide for MS1 and widest for 
MS2. High purity nitrogen was used as 
source and collision gas. For data analysis 
Waters Masslynx software was used. The run 
was performed with gradient of 0.1% formic 
acid in water (A) and 0.1% formic acid in 
acetonitrile (B). Flow rate was 0.2 mL/min 
and injection volume was 10 µL. 
Sample Preparation  
Plasma (Venipuncture) 
A 500 μL plasma that contained 6-MP 10 μg/ 
mL and 6-MMP 30 μg/mL were mixed with 
50 μl 5-FU 30 μg/mol by vortex mixing for 1 
min in a centrifuge tube. The solutions were 
added with 5 mL dichloromethane and then 
were vortexed for 2 mins. The tube was then 
centrifuged for 20 min at 3000 rpm. The 
organic phase as much as 3 mL was 
evaporated with N2 for 20 min at 60°C. The 
residue was then reconstituted with 200 μL 
mobile phase (air-methanol-acetonitrile, 
90:7:3, v/v, and 30 μL aliquot were injected 
onto the HPLC system.  
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Whole Blood (Dried Blood Spot) 
An aliquot of 40 µL spiked blood was spotted 
on the sampling paper with a graded 
capillary tube and dried for a minimum of 3 
h. cut the spot with 8 mm diameter. After 
that, transferred it into a 5 ml polypropylene 
tube. Add 100 µL IS, then extract it with 
methanol-acetonitrile (3:1), vortex for about 
30 s and sonicated for 25 min at 60 0C 
temperature, then centrifuged (room 
temperature, 3100×g, 15 min). Supernatant 
transferred in the sample tube and 
evaporated under a gentle stream of nitrogen 
at 40 0C temperature. After reconstituting 
the extract with 100 µLmobile phase, vortex 
for about 30 s and centrifuge (room 
temperature, 3100×g, 5 min), 10 µL of each 
sample was analyzed by LC-MS/MS. 
Method Validation 
Validation of the developed method was 
carried out as per EMEA guidelines for 
selectivity, carry-over, LLOQ, accuracy, 
precision, linearity, dilution integrity, matrix 
effect, and stability [1, 8]. 
Selectivity  
Selectivity is the ability of analytical method 
to differentiate the compounds of interest 
with the endogen components in the matrix 
or other compounds in the sample using at 
least 6 individual sources of matrix. The 
analysis was performed using plasma spiked 
with the compounds of interest at lower 
concentration (LLOQ). % diff and % CV 
should be ≤ ±20% for LLOQ and 5% for 
internal standard. 
Carry-Over  
Carry-over was performed by injecting blank 
sample after upper limit of quantification 
(ULOQ) concentration sample. A carry over ≤ 
±20% for LLOQ and ≤ ±5% for internal 
standard are acceptable. 
Lower Limit of Quantification (LLOQ)  
LLOQ was validated using five replicates of 
matrix which were spiked with 6-MP and 6-
MMP at LLOQ concentration. % diff and % 
CV should be ≤ ± 20%. 
Calibration Curves  
A blank sample, a zero sample and sample at 
7 calibration concentration levels were 
prepared. The slope, intercept and correlation 
coefficient of each calibration curve were 
determined. % diff should be ≤ ± 15% for each 
calibration concentration and ≤ ± 20% for 
LLOQ. 
Accuracy and Precision 
Accuracy and precision of the method were 
performed within-run and between-run. 
Accuracy and precision were determined at 
four concentrations stated as LLOQ, LQC, 
MQC, HQC. Accuracy was calculated as the 
mean percent deviation from the actual 
concentration expressed as % diff while 
precision was expressed by % CV calculated. 
Both parameters should be ≤ ±15% for the 
QC samples and should be ≤20% for LLOQ.  
Dilution Integrity 
Dilution of samples should not affect the 
accuracy and precision. If applicable, dilution 
integrity should be demonstrated by spiking 
the matrix with an analyze concentration 
above the ULOQ and diluting this sample 
with blank matrix (at least five 
determinations per dilution factor). Accuracy 
and precision should be within the set 
criteria, within ±15%.  
Matrix Effect 
Matrix effects should be investigated when 
using mass spectrometric methods. Matrix 
effect was assessed using at least 6 lots of 
blank matrix from individual donors. This 
was done by comparing the peak areas in the 
presence of matrix with the peak areas in 
pure solution of analyze. Matrix effect should 
be done at LQC and HQC. 
Stability  
Evaluation of stability was determined by 
analyzing samples containing 6-MP and 6-
MMP at LQCand HQC. The stability 
evaluation consisted of the stock and working 
solutions of the analyze and internal 
standard stability, freeze and thaw stability 
(no for DBS), and long term stability. 
Result and Discussion 
Bio-sampling Venipuncture Analyzed 
Using HPLC 
 
Result of lower limit of quantification (LLOQ) 
of 6-mercaptopurine was 2 ng/mL and had a 
value of % diff -4.62 - -3.87% and % RSD of 
3.89%. While LLOQ of 6-
methylmercaptopurine was 20 ng/mL and % 
diff was 4.24 - 14.11% and % RSD of 3.67%. 
The value of % diff and % RSD still meet the 
requirements so this concentration is selected 
as LLOQ.  
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Selectivity test was performed at a 
concentration of 2 ng/mL for 6-MP and 20 
ng/mL for 6-MMP using six different human  
plasma blank to see the effect of plasma 
impurities from different sources no more 
than ± 20% values of % diff and % CV.  
 
 
 
Figure 1: Chromatograms HPLC of standards solution (A), blank plasma (B), and LLOQ (C) 
 
Therefore, there was no interference at the 
retention time of analyze, metabolite, and 
internal standard (shown in figure 1). A 
calibration curve of 6-MP made were 2-200 
ng/mL, the correlation coefficient of 0.9991 
with the line equation y = 0.0004 + 0,0025x 
and 6-MMP made were 20-1500 ng/mL, had a 
coefficient correlation of 0.9993 with the line 
equation y = -0.0014 + 0,0006x. That no more 
than ± 15% for concentration besides LLOQ 
and no more than ± 20% for LLOQ 
concentration. Accuracy and precision test  
 
 
were performed within-run and between-run. 
Four selected concentrations covered a high, 
medium and low range and the lower limit of 
quantification of the calibration curve. 
Accuracy was evaluated by calculating the 
difference between measured values and 
nominal values (% diff), precision was 
calculated based on the coefficient of 
variation (% CV). Therefore, all analyses 
were detected with sufficient accuracy and 
precision (± 20% for LLOQ, ± 15% for LQC, 
MQC, HQC) (accuracy and precision data in 
Table 1 and 2).  
 
Table 1: Accuracy and precision of 6-mercaptopurine   
Analyze Actual concentration 
(ng/ml) 
Mean measured 
concentration (ng/ml) ± SD 
(n=5) 
Precision (% 
CV) 
Bias (% diff) 
Within-run LLOQ (2) 1.91 ± 0.05 2.53 (-2.48-8.66) 
 LQC (6) 5.78 ± 0.09 1.69 (-1.51-5.43) 
 MQC (100) 102.34 ± 2.33 2.28 (-0.08-5.06) 
 H QC (150) 159.72 ± 1.00 0.63 (5.51-7.01) 
Between-run LLOQ (2) 2.17 ± 0.05 2.37 (4.34-11.05) 
 LQC (6) 5.91 ± 0.11 1.81 (-4.48-0.14) 
 MQC (100) 104.52 ± 5.04 4.84 (0.12-10.46) 
 HQC (150) 149.01 ± 1.28 0.86 (-2.04-0.30) 
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Table 2: Accuracy and precision of 6-methylmercaptopurine 
Analyte Actual concentration 
(ng/ml) 
Mean measured 
concentration (ng/ml) ± SD 
(n=5) 
Precision (% 
CV) 
Bias (% diff) 
Within-run LLOQ (20) 20.62 ± 0.56 2.57 (0.08-6.50) 
 LQC (60) 59.63 ± 0.52 0.88 (-1.60-0.36) 
 MQC (1000) 992.41 ± 8.19 0.83 (-0.02-1.53) 
 HQC (1500) 1608.29 ± 1.97 0.12 (7.03-7.35) 
Between-run LLOQ (20) 21.81 ± 0.19 0.88 (8.15-10.08) 
 LQC (60) 60.08 ± 0.78 1.31 (-1.40-1.44) 
 MQC (1000) 1002.78 ± 4.02 1.40 (-0.68-2.56) 
 HQC (1500) 1501.89 ± 12.24 0.82 (-1.31-0.68) 
Note: LLOQ = lower limit of quantification, LQC = low quality control, MQC = medium quality 
control, QCH = high quality control 
 
Dilution integrity at half ULOQ was 0.63 % 
CV and -0.56-1.02 % diff for 6-MP, 1.03 % CV 
and -1.31-2.15 % diff for 6-MMP. At a 
concentration quarter ULOQ was 1.89 % CV 
and -10.83-0.71 % diff for 6-MP, 2.24 % CV 
and -4.85%-0.75% % diff for 6-MMP. 
Therefore, all analyses were detected with 
sufficient accuracy (± 15% relative error of 
the nominal value) and precision (within 15% 
relative standard deviation).  
 
Stock solution stability test remained stable 
at least for 21 days for storage at 4°C. 
Researchers made only one stock solution 
that can be used along the research as long 
as it still meets the limit of stability 
requirements. The freeze-thaw stability test 
was performed using LQC and HQC and then 
stored for three cycles of freeze and thaw. 
The freeze-thaw stability 6-MP was -14.52--
0.19 % diff for LQC and -13.05-1.22 % diff for 
HQC. While the % diff of 6-MMP at LQC and 
HQC were -12.55-0.97% and -7.08-1.93%, 
respectively. Therefore, the solutions were  
stable after three cycles of freeze and thaw. 
Long-term stability was performed at LQC 
and HQC. The samples were stored on days 
0, 7, 14, and 21. Based on the result, LQC 
and HQC of 6-MP and 6-MMP were still 
stable until day 21st with % diff value for 6-
MP were -14.79-4.38% and -5.68-4.50%, 
respectively, while for 6-MMP were -10.96-
1.59% and 3.56-7.46%, respectively. 
Bio-sampling Dried Blood Spot Analyzed 
Using LC-MS/MS 
Mass detection was performed on Waters 
Xevo TQD with electrospray ionization (ESI) 
positive for 6-MMP and 6-MMP and ESI 
negative for 5-FU. The following operational 
parameters of the MS detector were 
optimized; MS ion mode, Precursor and 
product ions cone and collision energies are 
presented in table 3. 6-Mercaptopurine was 
detected at m/z 153.03>119.10, 6-
methylmercaptopurine was detected at m/z 
167.17>126.03(shown in figure 2) and 5-
fluorouracil was used as internal standard at 
m/z 129.055>42, 02. 
 
  Figure 2: Fragmentation of ion mass spectra of 6-mercaptopurine (A) and 6-methylmercaptopurine (B) 
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Validation Assay 
The calibration curves were linear over the 
concentration range of 26-1000ng/mL for 6-
MP and 13-520 ng/mL for 6-MMP with a 
correlation coefficient of 0.99. The correlation 
coefficient from five replicate calibration 
curves on different days was more than 0.99.  
 
The lower limit of quantification (LLOQ) was 
26 ng/mL (6-MP) and 13ng/mL (6-MMP) with 
a coefficient of variation of less than 20%. 
The selectivity result showed that there was 
no interference endogenous compound from 
the blank whole blood of the six different 
sources, whereas the % diff both of 6-MP and 
6-MMP were less than 20% (shown in figure 
3). 
 
 
Figure 3: Chromatograms LC-MS/MS of standards solution (A), blank matrix (B), and LLOQ (C) 
 
Carry-over value after high concentration 
injection was 14.05% for 6-MP and 3.57% for 
6-MMP from LLOQ response while the carry-
over of internal standard was 1.08%. 
 
Precision and accuracy were calculated by 
within-run and between-run variation of QC 
sample in five replicates at four 
concentrations. Accuracy was evaluated by 
calculating the difference between measured 
values and nominal values (% diff), precision 
was calculated based on the coefficient of  
 
variation (% CV). Within-run accuracy and 
precision respectively were -12.76-11.90 % 
diff and 3.79-6.95 % CV for 6-MP, for 6-MMP 
was -19.92-9.41 % diff and 13.15-6.13 % CV. 
The between run accuracy and precision 
ranged -15.40-17.96 % diff and 3.09-9.22% 
CV for 6-MP, for 6-MMP was -15.52-19.62% 
diff and 0.91-4.28% CV. Therefore, all 
analyses were detected with sufficient 
accuracy and precision (± 20% for LLOQ, ± 
15% for LQC, MQC, and HQC). The within-
run and between-run precision and accuracy 
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values indicate the adequate reliability and 
reproducibility of the method within the 
analytical range.  
 
Dilution integrity at half ULOQ was 11.37 % 
CV and -6.68-13.55 % diff for 6-MP, 6.58 % 
CV and -13.36-4.30 % diff for 6-MMP. At a 
concentration quarter ULOQ was 3.14 % CV 
and 5.73-13.88 % diff for 6-MP, 9.49 % CV 
and -10.14-4.30 % diff for 6-MMP. Therefore, 
all analyses were detected with sufficient 
accuracy (± 15% relative error of the nominal 
value) and precision (within 15% relative 
standard deviation) Matrix effects were 
investigated for 6-MP and 6-MMP using 6 
lots of individual human blood. Ion 
increasing effects due to matrix constituents 
were observed which the value of matrix 
factors (MF).  
 
The internal standard normalized matrix 
factors (MEIS) were found to be 8.40-10.06 % 
CV for 6-MP, 7.66-8.07 % CV for 6-MMP.The 
MF value than less 100%, it concludes that 
indicated matrix compound causes ion 
suppression that can interfere with analyze 
ionization process, but % CV values were 
within limits requested by EMEA guidelines 
[1,9] (matrix effects data in Table 3). The 
stability test of 6-MP, 6-MMP and 5-FU were 
evaluated under different temperature and 
storage condition and were performed at LQC 
and HQC in three replicates.  
 
 Table 3: Matrix effects for 6-mercaptopurine and 6-methylmercaptopurine 
Blood 
lot 
Concentration 
(ng/ml) 
MF 
6-MP (%) 
MF IS 
(%) 
MEIS 
(%) 
MF 
6-MMP (%) 
MF 
IS (%) 
MEIS 
(%) 
1 LQC (104 for 6-MP, 
52 for 6-MMP) 
 
69.57 82.00 0.84 83.91 82.00 1.02 
2 83.43 80.65 1.03 79.19 80.65 0.98 
3 83.46 83.15 1.00 83.83 83.15 1.01 
4 78.61 82.64 0.95 97.67 82.64 1.18 
5 80.67 80.67 1.00 95.58 80.67 1.18 
6 90.09 82.72 1.08 83.14 82.72 1.01 
1 HQC (820 for 6-MP, 
416 for 6-MMP) 
76.66 82.00 0.93 91.31 82.00 1.11 
2 70.64 80.65 0.87 80.39 80.65 0.99 
3 66.94 83.15 0.80 88.51 83.15 1.06 
4 63.58 82.64 0.76 80.58 82.64 0.97 
5 67.13 80.67 0.83 73.46 80.67 0.91 
6 85.24 82.72 1.03 85.18 82.72 1,03 
 
 
The result of stability test showed that 
analyses in stock solution stable at least for 
16 d storage of -20 oC. Analyte in DBS was 
stable for 6 d at room temperature and 24 h 
in the autosampler. 
Conclusion 
The developed method is valid for 6-MP and 
6-MMP simultaneously in vitro from 
venipuncture using HPLC and from dried 
blood spot using LC-MS/MS and showed good 
selectivity, linearity [10], accuracy and 
precision, matrix effect and stability. 
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